TLR7 and neoplasm: Additionally, TLR7/8 agonist MEDI9197 combined with immune checkpoint inhibitors PD-1 blockade can polarize TAMs toward anti-tumor phenotypes and activate CD8+ T cells and NK cells, leading to a better efficacy (143).